3D Systems (DDD, Financial) has received FDA approval for its innovative 3D bioprinting technology aimed at repairing peripheral nerve damage. In collaboration with TISSIUM, a French MedTech pioneer in biomorphic programmable polymers, the company developed a custom 3D printing solution. This solution integrates TISSIUM's advanced polymers with 3D Systems' cutting-edge bioprinting methods.
The collaboration has resulted in a fully bioabsorbable 3D-printed medical device specifically designed for nerve repair, utilizing a unique photopolymer. Named COAPTIUM CONNECT with TISSIUM Light, this device offers a first-of-its-kind, sutureless method for repairing peripheral nerves, providing an atraumatic solution for patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for 3D Systems Corp (DDD, Financial) is $2.67 with a high estimate of $4.00 and a low estimate of $2.00. The average target implies an upside of 91.85% from the current price of $1.39. More detailed estimate data can be found on the 3D Systems Corp (DDD) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, 3D Systems Corp's (DDD, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 3D Systems Corp (DDD, Financial) in one year is $4.05, suggesting a upside of 191.37% from the current price of $1.39. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 3D Systems Corp (DDD) Summary page.
DDD Key Business Developments
Release Date: May 13, 2025
- Revenue: $95 million, a decline of 8% from the prior year.
- Industrial Solutions Revenue: $53 million, a 7% decline driven by material sales shortfall.
- Healthcare Solutions Revenue: $41 million, a 9% decrease with growth in services offset by declines in materials.
- Gross Profit Margin: 35%, down from 40% in the prior year.
- Non-GAAP Operating Expense: $61.6 million, a $5 million improvement from the prior year.
- Adjusted EBITDA: Negative $23.9 million, a $4 million decline from the prior year.
- Non-GAAP Loss Per Share: $0.21, compared to a loss of $0.17 in the prior year.
- Cash and Cash Equivalents: $135 million at the end of the quarter, with a post-divestiture increase to approximately $250 million.
- Cost Savings Initiatives: $70 million total expected savings, including $20 million incremental savings for 2025.
- Geomagic Sale Proceeds: Increased cash by nearly $120 million.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- 3D Systems Corp (DDD, Financial) has completed a comprehensive refresh of its polymer and metal product lines, positioning itself with industry-leading printing solutions.
- The company has maintained a high level of R&D investment, over 20% of revenue, which is higher than its competitors, indicating a strong focus on innovation.
- 3D Systems Corp (DDD) has successfully insourced its manufacturing operations, which is expected to enhance quality control and reduce costs.
- The company's personalized healthcare and medical parts manufacturing businesses grew revenues by 18% and 17%, respectively, year-over-year.
- 3D Systems Corp (DDD) has a strong cash position following the sale of its Geomagic asset portfolio, providing financial flexibility for future strategic initiatives.
Negative Points
- The company is experiencing weak sales due to a freeze in customer capital spending, largely driven by tariff uncertainties.
- 3D Systems Corp (DDD) reported a decline in consolidated revenues by 8% year-over-year, with significant declines in materials sales.
- Non-GAAP gross profit margin decreased from 40% to 35% year-over-year, primarily due to lower volumes and unfavorable price and mix.
- The company has withdrawn its full-year guidance for 2025 due to ongoing economic and geopolitical instabilities and tariff uncertainties.
- 3D Systems Corp (DDD) is implementing cost reduction initiatives, including a $70 million cost-saving plan, which may impact growth if not managed carefully.
